Avid Bioservices Inc (CDMO)

[entdoc]

volgoat and cloaked: of paramount import for PPHM stockholders and prospectives is to remember the present iteration [sic {rrdog}]of Bavi is the result of one investigational detour along the pathway of exploring Bavi-(anti-phospholipid) technology. the "holy grail" is undoubtedly an oralMAB which can be taken daily similar to oral insulin. But walk we must before running. Today's Bavi is but the "crawling" infant form trying to force its way onto a very impacted treatment table. I am certain that immunogenicity is important here. No question. But the term "immunogenicity" is usually used when looking for a body's ["allergic"]reaction to a drug. We think we know that Bavi- chimeric form is relatively free of side effects, but do we have a clue about how many times current-Bavi can be given before host vs. Bavi reaction sets in? I am sure the company knows the answer to that one. Humanized Bavi being used for cancer imaging doesn't appear to lose specificity for docking to cancer-PS docking sites and lose docking affinity "by many orders of magnitude" as suggested by your bro, volgoat. I am really interested in reading the research on this. I do remember seing in the literature that chimeric Bavi loses docking-site affinity when it it is carrying a payload. Bottom line. This technology is HUGE, and the advantage conferred on PPHM by virtue of its vast experience using the technology in humans is enormous. WE have paid for that human research (and lower animal experiments too), and to conclude that results on advanced lung and cancer patients render Bavi (Bavi technology) worthy only of the trash heap is not reasonable.